Xintela recruits Rickard Mosell as Head of Business Development
On 12 September 2016, Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016. Rickard Mosell will leave his current position as CEO of Ideon Innovation and will be responsible for Xintela’s business development and financing. Rickard Mosell will also be a member of Xintela’s management team. Rickard […]
Xintela receives 1,5 MSEK in dispute settlement
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation. The background to the dispute is that the counter party, who had an assignment from Xintela to validate one of the company’s patents, missed the deadline for validation with the consequence that the patent was not validated in […]
Xintela engages professor Christer Betsholtz as scientific an strategic advisor
Xintela announces that Christer Betsholtz has been engaged as a scientific and strategic advisor for the company’s cancer programme, with a focus on the brain cancer form glioblastoma. Betsholtz is a professor at the University of Uppsala with a focus on vascular biology and, in addition, from August 1 2016 will be head of the […]
Xintela strengthens its organisation with the appointment of Caroline Ehrencrona as Director Clinical Development and Regulatory Affairs
Xintela announces the appointment of Caroline Ehrencrona to a role responsible for the company’s Clinical Development and Regulatory Affairs operations. Caroline Ehrencrona takes up the post on June 1 2016 and will strengthen Xintela’s operations for upcoming clinical studies and will be responsible for the day-to-day contact with regulatory authorities. Caroline Ehrencrona has more than […]
Xintela initiates a study on the treatment of cartilage damage in horses in the USA
Xintela AB (publ) announces today that the company have initiated a study, in the USA, on the treatment of cartilage damage in horses. The study is being conducted in collaboration with an eminent research group at Cornell Univesity. Xintela’s stem cells have been injected into horse joints and the study is expected to be completed […]
